skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 16.11d (Release date: 2016-11-28)
SearchBox Top
SearchBox Bottom
Cabozantinib (Code C52200)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Cabozantinib

Definition: An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

Label: Cabozantinib

NCI Thesaurus Code: C52200 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3181682  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-
CABOZANTINIB
Cabozantinib
N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide

External Source Codes: 
CAS Registry Number 849217-68-1 (see NLM ChemIDplus info)
FDA UNII Code 1C39JW444G
UMLS CUI C3181682

Other Properties:
Name Value (qualifiers indented underneath)
Chemical_Formula C28H24FN3O5
code C52200
Contributing_Source FDA
Legacy_Concept_Name XL184
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52200

Mainbox Bottom